| Bioactivity | Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of hypoxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research[1][2][3][4]. | |||||||||
| CAS | 128298-28-2 | |||||||||
| Formula | C17H20N2O | |||||||||
| Molar Mass | 268.35 | |||||||||
| Appearance | 固体 | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Schachter SC, et al. Remacemide: current status and clinical applications. Expert Opin Investig Drugs. 2000 Apr;9(4):871-83. [2]. Dyker AG, et al. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke. 1999 Sep;30(9):1796-801. [3]. Greenamyre JT, et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol. 1994 Jun;35(6):655-61. [4]. Kieburtz K, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord. 1996 May;11(3):273-7. |
Remacemide
CAS: 128298-28-2 F: C17H20N2O W: 268.35
Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neu
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.